NO20074610L - Fremgangsmate for a bestemme mottakeligheten til CHK1 inhibitorer - Google Patents

Fremgangsmate for a bestemme mottakeligheten til CHK1 inhibitorer

Info

Publication number
NO20074610L
NO20074610L NO20074610A NO20074610A NO20074610L NO 20074610 L NO20074610 L NO 20074610L NO 20074610 A NO20074610 A NO 20074610A NO 20074610 A NO20074610 A NO 20074610A NO 20074610 L NO20074610 L NO 20074610L
Authority
NO
Norway
Prior art keywords
chk1
patient
determining susceptibility
chk1 inhibitors
signal transmission
Prior art date
Application number
NO20074610A
Other languages
English (en)
Norwegian (no)
Inventor
Sonya Zabluoff
Louise Bergeron
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20074610L publication Critical patent/NO20074610L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20074610A 2005-02-18 2007-09-11 Fremgangsmate for a bestemme mottakeligheten til CHK1 inhibitorer NO20074610L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65413105P 2005-02-18 2005-02-18
PCT/GB2006/000548 WO2006087557A1 (en) 2005-02-18 2006-02-16 METHOD FOR DETERMINING RESPONSIVENESS TO CHKl INHIBITORS

Publications (1)

Publication Number Publication Date
NO20074610L true NO20074610L (no) 2007-11-14

Family

ID=36295309

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074610A NO20074610L (no) 2005-02-18 2007-09-11 Fremgangsmate for a bestemme mottakeligheten til CHK1 inhibitorer

Country Status (23)

Country Link
US (1) US20080145358A1 (de)
EP (1) EP1853721B1 (de)
JP (1) JP2008530575A (de)
KR (1) KR20070107034A (de)
CN (1) CN101120096A (de)
AT (1) ATE464395T1 (de)
AU (1) AU2006215413B2 (de)
BR (1) BRPI0607798A2 (de)
CA (1) CA2598185A1 (de)
CY (1) CY1110076T1 (de)
DE (1) DE602006013604D1 (de)
DK (1) DK1853721T3 (de)
ES (1) ES2341796T3 (de)
HR (1) HRP20100313T1 (de)
IL (1) IL184873A0 (de)
MX (1) MX2007010073A (de)
NO (1) NO20074610L (de)
NZ (1) NZ556718A (de)
PL (1) PL1853721T3 (de)
PT (1) PT1853721E (de)
SI (1) SI1853721T1 (de)
WO (1) WO2006087557A1 (de)
ZA (1) ZA200706670B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2086580A2 (de) * 2006-11-21 2009-08-12 Merial Limited Prime-boost-impfstoff gegen die canine leishmaniose
US8173366B2 (en) 2007-03-29 2012-05-08 University of Pittsburgh—of the Commonwealth System of Higher Education Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer
US8263329B2 (en) 2007-03-29 2012-09-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer
GB0720113D0 (en) * 2007-10-15 2007-11-28 Cambridge Cancer Diagnostics L Diagnostic, prognostic and predictive testing for cancer
JP5436786B2 (ja) * 2008-03-06 2014-03-05 オリンパス株式会社 細胞周期計測方法
WO2010076887A1 (en) * 2009-01-05 2010-07-08 Banyu Pharmaceutical Co.,Ltd. Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
WO2016126616A1 (en) 2015-02-02 2016-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and kits for measuring and quantifying dna double-stranded breaks using gamma-h2ax and h2ax
KR20180126085A (ko) * 2016-05-05 2018-11-26 난토믹스, 엘엘씨 체크포인트 부전 및 그 방법(checkpoint failure and methods therefor)
EP3499228A4 (de) * 2016-08-12 2020-04-15 Hitachi Chemical Company, Ltd. Verfahren zum nachweis von zirkulierenden tumorzellen und vorbehandlungsverfahren zur detektion von zirkulierenden tumorzellen
KR20220054644A (ko) * 2019-09-03 2022-05-03 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 환자 상태를 결정하기 위한 방법 및 제제
CA3261094A1 (en) 2022-07-13 2024-01-18 Acrivon Therapeutics, Inc. METHODS AND SYSTEMS FOR TREATING A DISEASE USING AN ATR/CHK1 SIGNALING PATHWAY INHIBITOR

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001161398A (ja) * 1999-12-06 2001-06-19 Igaku Seibutsugaku Kenkyusho:Kk タンパク質リン酸化酵素の活性測定方法およびタンパク質リン酸化酵素の活性測定キット
PL378372A1 (pl) * 2003-01-09 2006-04-03 Pfizer Inc. Tricykliczne związki jako inhibitory kinaz białkowych do wzmacniania skuteczności środków przeciwnowotworowych i radioterapii
EP1613625A1 (de) * 2003-03-14 2006-01-11 AstraZeneca AB Neue kondensierte triazolone und ihre verwendung
JP4597976B2 (ja) * 2003-04-17 2010-12-15 アルナイラム ファーマシューティカルズ インコーポレイテッド 修飾ｉＲＮＡ剤
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
US20050207998A1 (en) * 2003-07-21 2005-09-22 Yaoping Lu Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer
AU2004274013A1 (en) * 2003-09-17 2005-03-31 Icos Corporation Use of Chk1 inhibitors to control cell proliferation

Also Published As

Publication number Publication date
EP1853721B1 (de) 2010-04-14
ZA200706670B (en) 2008-10-29
DE602006013604D1 (de) 2010-05-27
BRPI0607798A2 (pt) 2010-06-22
NZ556718A (en) 2010-10-29
PL1853721T3 (pl) 2010-08-31
KR20070107034A (ko) 2007-11-06
HK1113059A1 (en) 2008-09-19
CY1110076T1 (el) 2015-01-14
DK1853721T3 (da) 2010-06-14
HRP20100313T1 (hr) 2010-07-31
ATE464395T1 (de) 2010-04-15
SI1853721T1 (sl) 2010-06-30
IL184873A0 (en) 2007-12-03
AU2006215413B2 (en) 2010-10-07
ES2341796T3 (es) 2010-06-28
EP1853721A1 (de) 2007-11-14
MX2007010073A (es) 2007-10-10
WO2006087557A1 (en) 2006-08-24
CN101120096A (zh) 2008-02-06
PT1853721E (pt) 2010-06-08
US20080145358A1 (en) 2008-06-19
AU2006215413A1 (en) 2006-08-24
JP2008530575A (ja) 2008-08-07
CA2598185A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
ZA200706670B (en) Method for determining responsiveness to CHK1 inhibitors
ZA200805787B (en) Detection of cancer by elevated levels of BCL-2
ATE539165T1 (de) Verfahren zum nachweis von beta-lactamase
EP1810026A4 (de) B7-h1 und verfahren zur diagnose, prognose und behandlung von krebs
EP2350630A4 (de) Vorrichtung und verfahren für den nachweis eines analyts aus einer probe
EP1849001A4 (de) Seitenstrom-testsatz und verfahren zum nachweis eines analyten
WO2010056337A3 (en) Methods and systems of using exosomes for determining phenotypes
WO2010067358A3 (en) Methods and kits for direct detection and susceptibility profiling of beta-lactam resistant bacteria
DK2046986T3 (da) Transkriptionsutroskab, detektion og anvendelse deraf
EP1692102A4 (de) Zusammensetzungen und verfahren zum nachweis und zur behandlung von krankheiten und leiden, die mit chemokinrezeptoren im zusammenhang stehen
EP2212700B8 (de) Verfahren zur beurteilung von kolorektalem krebs anhand einer stuhlprobe durch verwendung einer marker-kombination aus calprotectin und einem hämoglobin/haptoglobin-komplex
EA201000734A1 (ru) Способ и аппарат для мониторинга пространственного образования фибринового сгустка
WO2005031005A3 (en) Compositions, methods and kits for determining the presence of trichomonas vaginalis in a test sample
EP1994172A4 (de) Verfahren zur diagnose und/oder vorhersage der entwicklung einer allergischen erkrankung und agentien zur behandlung und/oder vorbeugung davon
DK2185939T3 (da) Engangsanalyseudstyr med mikroprocessor
MX2007002908A (es) Sondas inmovilizadas y metodos para detectar proteinas prionicas alteradas conformacionalmente.
WO2003103481A3 (en) Methods for detecting b. anthracis infection
MX2009008525A (es) La determinacion cuantitativa de risedronato en orina mediante spe-lc-ms-ms.
EP1924710A4 (de) Verfahren zur diagnose eines ovarialkarzinoms und kits dafür
EP2585832A4 (de) Reduzierung falscher ergebnisse von testmessungen
EP2268800A4 (de) Neu identifiziertes humanes rhinovirus des typs hrv-c und verfahren und kits zum nachweis des typs hrv-cs
DE60306865D1 (de) Detektion von Vancomycin-resistenten Enterococcus-Subspezies
FR2880426B1 (fr) Procede et dispositif pour la determination du point de fumee des hydrocarbures
EP2102393A4 (de) Für platin-koordinationskomplex-induzierte ototoxizität prädiktive polymorphismen
WO2007047335A3 (en) Methods for use with baff antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application